Spark Therapeutics and Pfizer amend License Agreement for SPK-9001
Spark Therapeutics and Pfizer announced they have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B. Spark Therapeutics…
Read More...
Read More...
